Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"

This article was originally published in The Tan Sheet

Executive Summary

FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
Advertisement

Related Content

OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Bayer Rid Pediculicide Marketing Begins With Mousse Launch
ANDA approvals
Non-Monograph Drugs Interim Marketing Preservation Urged By CHPA
"dNDAs"
Rid mousse
Rid mousse

Topics

Advertisement
UsernamePublicRestriction

Register

PS090965

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel